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Abstract
CC chemokine ligand 2 (CCL2, also known as monocyte chemoattractant protein-1) has been demonstrated to recruit
monocytes to tumor sites. Monocytes are capable of being differentiated into tumor-associated macrophages
(TAMs) and osteoclasts (OCs). TAMs have been shown to promote tumor growth in several cancer types. Osteo-
clasts have also been known to play an important role in cancer bone metastasis. To investigate the effects of CCL2
on tumorigenesis and its potential effects on bone metastasis of human prostate cancer, CCL2 was overexpressed
into a luciferase-tagged human prostate cancer cell line PC-3. In vitro, the conditioned medium of CCL2 overex-
pressing PC-3luc cells (PC-3lucCCL2) was a potent chemoattractant for mouse monocytes in comparison to a condi-
tioned medium from PC-3lucMock. In addition, CCL2 overexpression increased the growth of transplanted xenografts
and increased the accumulation of macrophages in vivo. In a tumor dissemination model, PC-3lucCCL2 enhanced the
growth of bone metastasis, which was associated with more functional OCs. Neutralizing antibodies targeting both
human and mouse CCL2 inhibited the growth of PC-3luc, which was accompanied by a decrease in macrophage
recruitment to the tumor. These findings suggest that CCL2 increases tumor growth and bone metastasis through
recruitment of macrophages and OCs to the tumor site.
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Introduction
Prostate cancer is the most commonly diagnosed lethal malignancy
in men in the United States [1]. Although androgen-dependent
metastatic prostate cancer is initially treatable by castration, advanced
prostate cancer remains incurable owing to the inevitable emergence
of androgen-independent cells [2]. New approaches to the treatment
of metastatic prostate cancer are needed. One such approach is to
identify novel targets based on cancer cell–tumor microenvironment
interactions [3–7].
CC chemokine ligand 2 (CCL2, also known as monocyte chemo-
tactic protein-1) is a member of the CC beta chemokine family that is
produced by macrophages, fibroblasts, and endothelial cells to stimu-
late chemotaxis of monocyte/macrophages and other inflammatory
cells through its receptor, CCR2 [8]. Monocytes recruited to the tumor
site adopt a macrophage phenotype that is dictated by the presence
of specific cytokines. Mature macrophages are divided into M1 (classi-
cally activated) and M2 (alternatively activated) phenotypes. Tumor-
associated macrophages (TAMs) of the M2 phenotype secrete several
growth factors (transforming growth factor β, vascular endothelial
growth factor, etc.) that promote tumor growth [9–13]. In several
cancers, CCL2 has previously been shown to be an important deter-
minant of tumor growth [14–16]. CCL2 promotes prostate cancer cell
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proliferation, migration, and survival from autophagic cell death
through Akt phosphorylation–dependent mechanisms in vitro and
in vivo [16,17]. The PC-3 cell line was established from human pros-
tatic adenocarcinoma bone metastasis [18]. Neither expression of an-
drogen receptor nor response to androgens was reported; therefore,
the PC-3 cell line has been used as an androgen-independent cell model
[19]. To further investigate the effects of CCL2 on tumorigenesis, met-
astatic potential, and the tumor microenvironment of human prostate
cancer cells, human CCL2 DNAwas introduced into the human pros-
tate cancer cell line with the luciferase gene, PC-3luc, by lentivirus stable
transfection. In this study, CCL2 increased prostate cancer growth and
bone metastasis in vivo and was accompanied by the recruitment of
macrophages and osteoclasts (OCs).
Materials and Methods
Cell Culture and Transfection
Human prostate cancer PC-3luc cells were generated as previously de-
scribed [16] and were cultured in RPMI-1640 (GIBCO, Grand Island,
NY), 100 U/ml penicillin, and 100 μg/ml streptomycin supplemented
with 10% fetal bovine serum (GIBCO) under a humidified atmosphere
of 5% CO2 at 37°C. Human CCL2 DNA (Accession No. BC009716)
was produced by polymerase chain reaction (Takara Bio, Inc, Otsu,
Japan) and is subcloned into pLenti6/V5-DEST (Invitrogen, Carlsbad,
CA) vector with Gateway System (Invitrogen). The plasmid was pack-
aged into lentivirus by the University of Michigan Vector Core, using
psPAX2 and pMD2.Gmammalian expression lentiviral helper plasmids.
Transfected cells were selected by treatment with 5 μg/ml Blasticidin
(Invitrogen) for 14 days, and surviving cells were used for the following
experiment. Empty pLenti6/V5-DEST vector was used as amock vector.
Reverse Transcription–Polymerase Chain Reaction
RNAwas extracted byRNAeasyMicroKit (QIAGENGmbH,Hilden,
Germany) according to the manufacturer’s instructions. One micro-
gram of total RNA of each sample was reverse transcribed by a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA). To detect transfected vectors, Blasticidin sequence was used.
The primers for Blasticidin were as follows: Blasticidin-sense, 5′-AT-
CAACAGCATCCCCATCTC-3′; Blasticidin-antisense, 5′-ATGCA-
GATCGAGAAGCACCT-3′. The housekeeping transcript, β-actin,
was used as a control for semistandardization. The polymerase chain
reaction (PCR) products were analyzed by electrophoresis on 1% aga-
rose gels.
Proliferation Assays
Proliferation assays were previously described [16]. Briefly, cells were
seeded at a density of 1 × 104 cells in 96-well plates in RPMI-1640
complete medium. Cell growth was determined every 24 hours using
the WST-1 assay (Roche Diagnostic, Indianapolis, IN).
ELISA Assays
For preparing the conditioned medium, 3.0 × 105 PC-3lucMock and
PC-3lucCCL2 cells were seeded on six-well culture plates and cultured
for 72 hours with complete medium. The conditioned medium was
centrifuged, and the supernatant was collected and stored in −80°Cuntil
use. ELISA analysis for human CCL2 (R&D Systems, Minneapolis,
MN) was performed following the manufacturer’s instructions. CCL2
concentrations were normalized for cell number (1.0 × 106 cells/ml).
Migration Assay
For preparing the conditioned medium for the transwell assay,
PC-3lucMock and PC-3lucCCL2 cells were cultured in 75-mm2 tissue
culture flasks to be 60% to 70% confluent. Next, cells were washed
with PBS and cultured with RPMI-1640 supplemented with 1%
serum for 72 hours. The conditioned medium was normalized for
cell number. Mouse peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Paque PLUS (GE healthCare Bio-Sciences
AB, Uppsala, Sweden) density gradient centrifugation from male severe
combined immunodeficient mice (CB-17 SCID) peripheral blood
(Charles River, Chicago, IL). Cells at a density of 2.5 × 104 cells in
RPMI-1640 supplemented with 1% FBSwere plated in the inner cham-
ber of 24-well culture plates (8-μmpore size; BectonDickinson, Franklin
Lakes, NJ). The outer chamber was filled with RPMI (1% FBS) as a
negative control, 100 ng/ml recombinant human CCL2 (PeproTech,
Inc, Rocky Hill, NJ) as a positive control, and conditioned medium
of each cell line. After incubation for 24 hours, cells were fixed and
stained with 2% crystal violet, and cells inside the inserts were removed.
The number of migrated cells in the whole membrane was counted
under a microscope.
Prostate Cancer Xenograft Model In Vivo
Bioluminescent imaging of PC-3luc was done as previously described
[16]. Briefly, PC-3lucMock and PC-3lucCCL2 cells (1 × 105 and 2 × 105
cells for subcutaneous and intracardiac injections, respectively) were
introduced into CB-17 SCID mice (5-6 weeks of age). Mice were im-
aged weekly for 5 (subcutaneous) or 7 (intracardiac) weeks using a CCD
IVIS system with a 50-mm lens (Xenogen, Corp). The results were
analyzed using LivingImage software (Xenogen Corp, Alameda, CA).
In antibody treatment studies, CNTO888, a human IgG1k antibody
that neutralizes human CCL2, and CNTO1142, a rat/mouse chimeric
antibody (provided byDr. Linda Snyder, Centocor, Inc, Horsham, PA),
were injected intraperitoneally twice weekly.
Flow Cytometry
A total of 1 × 106 cells of each cell line (PC-3lucMock and PC-3lucCCL2)
were injected to generate tumors for flow cytometric analysis. At week 4,
8- to 10-mm-sized tumors were used. In the antibody treatment study,
xenograft tumors were harvested after 6 weeks. Tumors were digested
with collagenase (Sigma-Aldrich, St Louis, MO) and then made into
single cell suspension. Mononuclear cells were collected by layering in
Ficoll-Paque centrifuge. Macrophages were stained with fluorescein
isothiocyanate–conjugated anti–mouse Mac-3 (M3/86) antibody (BD
Bioscience Pharmingen, San Jose, CA) and their matching isotype con-
trols according to themanufacturer’s protocols. The cells were incubated
with antibodies for 30 minutes at 4°C and washed with PBS. The
samples were analyzed by using a FACSCalibur flow cytometer and
CellQuest software (Becton Dickinson).
Histology
Xenograft tumors were harvested after 6 weeks, fixed in 10% buff-
ered formalin, and then embedded in paraffin wax. Tumor metastases
of bones and jaws were harvested after 7 weeks. They were fixed in a
10% buffered formalin and decalcified before paraffin embedding.
Five-micrometer sections were cut and placed on glass slides and stained
with anti–mouse Mac-3 (M3/86) antibody at a 1:200 dilution for
identification of mouse macrophages. Bone samples were stained
with a tartrate-resistant acid phosphatase (TRAP) staining kit (Sigma).
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TRAP-positive and multinuclear cells on the bone surface were counted
as OCs in a blinded manner.
Statistics
Data were analyzed with GraphPad Prism4 software (GraphPad Soft-
ware Inc, La Jolla, CA). Either the Student’s t test (in vitro data analy-
sis) or the Mann-Whitney test (in vivo data analysis) was used for the
comparison between two groups as required. Significance was defined
as P < .05.
Results
Characterization of PC-3lucMock and PC-3lucCCL2 Cells
To confirm that both cell lines included vectors, mRNA of Blasti-
cidin, a selection maker, was identified by reverse transcription–PCR
(Figure 1A, upper panels). Blasticidin expression levels were similar.
CCL2 secretion by each of the cell lines cultured with complete me-
dium was measured by ELISA. PC-3lucCCL2 cells secreted 195.0 ng/ml
per 106 cells in the conditioned medium (Figure 1A, lower panel ) at
72 hours. The concentration of CCL2 secreted from PC-3lucMock cells
was below the detection range of the ELISA kit (∼2 pg/ml). In vivo cell
proliferation of these cell lines in complete medium (10% serum) did
not show a significant difference (Figure 1B). It was previously demon-
strated that human CCL2 partially binds to and activates the mouse
CCR2 receptor [20]. Next, the chemoattractant activity of CCL2 from
PC-3lucCCL2 in a transwell assay was examined. As expected, recombi-
nant human CCL2 affected the migration activity of mouse PBMCs.
The numbers of attracted PBMCs were similar in rhCCL2 (535.7 cells
per membrane) and PC-3lucMock (535.3 cells per membrane). In ad-
dition, PC-3lucMock attracted more PBMCs compared with the con-
trol (50.3 cells per membrane). The conditioned medium from
PC-3lucCCL2 cells attracted more mouse PBMCs compared with the
conditioned medium from PC-3lucMock cells (mock = 535.3 cells per
membrane, CCL2 = 1316.3 cells per membrane; Figure 1, C and D).
This result demonstrates that human CCL2 from PC-3lucCCL2 cells
attracts mouse PBMCs in vitro.
Overexpression of CCL2 Correlates with Local Prostate
Cancer Growth In Vivo
To evaluate the localized tumor growth of PC-3lucCCL2, an in vivo
model of prostate cancer growth was used. A total of 1 × 105 cells were
Figure 1. Characterization of CCL2 overexpression PC-3luc cells in vitro. (A) Expression of CCL2 in PC-3luc cell. Vectors’ transfection
was detected by reverse transcription–PCR (upper panels). The quantification of CCL2 secretion in supernatant was detected by ELISA
(lower panel). Values represent mean ± SD. (B) In vitro growth of PC-3lucMock and PC-3lucCCL2 with complete medium. Cell proliferation
was analyzed by WST-1 assay. Values represent mean ± SD (ns, not significant). (C) Mouse PBMC migration was analyzed in response
to rhCCL2 (100 ng/ml), PC-3lucMock, and PC-3lucCCL2 conditioned medium. The number of cells per whole membrane was manually counted
by microscopy. Columns: *P < .05 compared with control, #P < .05 compared with PC-3lucMock. Bars, SD. (D) Representative pictures of
migrated cells. Clockwise; control, rhCCL2 (100 ng/ml), conditioned medium from PC-3lucCCL2 and conditioned medium from PC-3lucMock.
Bars, 200 μm.
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transplanted by subcutaneous injection (n = 10 per group) to male
SCIDmice, and tumor growth was monitored weekly for up to 5 weeks.
As shown in Figure 2A, the average tumor growth of PC-3lucCCL2
was faster than that of the control. PC-3lucCCL2 continued growing after
4 weeks, whereas PC-3lucMock cells exhibited a trend of growth inhi-
bition after 4 weeks. At 5 weeks, the tumor burden of PC-3lucCCL2
was significantly higher when compared with the control (Figure 2, B
and C). The average tumor burden of PC-3lucCCL2 increased 3.4-fold.
Given that PC-3lucCCL2 cells did not grow faster in vitro than control
cells, it is likely that this increase was a result of CCL2 affects on cells
of the tumor microenvironment (Figure 1B).
CCL2 Recruits Macrophages to Tumor Sites
The effects of tumor derived CCL2 on macrophage recruitment in
prostate cancer was assessed in vivo using flow cytometry and immuno-
histochemistry (Figure 3, B and C ). Flow cytometric analysis of tumor-
infiltrated macrophages revealed that the PC-3lucCCL2 tumor contained
16.62%macrophages (18.29% in the representative experiment shown
in Figure 3A), whereas PC-3lucMock contained 7.76% macrophages
(8.09% in the representative experiment shown in Figure 3A). This
difference was also observed in immunostaining analysis for Mac-3
(Figure 3C).
Neutralizing Antibodies Targeting Both Mouse and Human
CCL2 Reduce Tumor Volume and Macrophage Recruitment
To inhibit CCL2 from both tumor and host cells, SCID mice were
treated with CNTO888, a human IgG1k antibody that neutralizes
human CCL2, and CNTO1142, a rat/mouse chimeric antibody that
neutralizes mouse CCL2/JE, 1 week before PC-3luc cell transplantation
(control group, n = 5; treatment group, n = 5). The mice were treated
twice per week with anti-CCL2 antibodies at 10 mg/kg until the end of
the study, and serial bioluminescent images were taken. At 5 weeks of
transplantation, CCL2 neutralizing antibody reduced tumor growth
by 83.7% on average compared with the control group (Figure 4A).
To further determine the efficacy of CCL2 inhibition in macrophage
recruitment,macrophages in the tumor were counted by flow cytometry
at 6 weeks. Of the control tumor cells, 45.8% were mouse macrophage,
whereas the percentage in the treatment tumor was reduced to 23.7%
on average (48.3% decrease compared with control; Figure 4B).
CCL2 Increases Tumor Burden and Bone Metastasis of
Prostate In Vivo
To further determine the effects of CCL2 overexpression on whole
body tumor burden and bone metastases, PC-3lucMock and PC-3lucCCL2
(2 × 105 cells per mouse) were introduced into male SCIDmice (mock,
n = 14; CCL2, n = 15) by intracardiac injection, and tumor burden
was monitored weekly for up to 7 weeks. By 4 weeks, the average
tumor burden of PC-3lucCCL2 was slightly lower than the control, and
at week 7, the average tumor burden of PC-3lucCCL2 increased 6.3-fold
compared with PC-3lucMock (P < .05; Figure 5, A and B). To determine
the effect of CCL2 in tumor sites within bone, growth was assessed
by counting photons within regions of interest on the seventh week
(jaw and bilateral lower limbs). The number of apparent metasta-
ses in the jaw and bilateral lower limbs was counted (PC-3lucMock =
15metastases/14mice, PC-3lucCCL2 = 24metastases/15mice); however,
a statistically significant difference was not achieved. Comparison of
region of interest values of apparent bone metastatic sites between con-
trol and PC-3lucCCL2 revealed a significant increase in tumor growth of
PC-3lucCCL2 in bone (P < .05; Figure 5, C and D) at week 7.
CCL2 Increases OCs in Bone Metastasis
Prostate cancer bone metastasis is generally considered to be osteo-
blastic owing to the unstructured bone formation [21–23]; however,
OC formation and recruitment in bone metastasis are essential to os-
teoblast activation [24–27]. To address the mechanism of increased
growth of PC-3lucCCL2 in the bone, OCs, recognized as TRAP staining
positive and multinuclei cells in bone metastases, were analyzed (n = 5
per group). As shown in Figure 6, the number of OCs in PC-3lucCCL2
bone metastases is significantly higher than that in PC-3lucMock (P < .05;
Figure 6C ). Many defined Howship lacunae as pits or concavities
Figure 2. In vivogrowth of PC-3lucMock and PC-3lucCCL2. (A) Local tumor xenograftswere established by subcutaneous injection of PC-3lucMock
and PC-3lucCCL2 to SCID mice (n = 10 mice per group), and tumor growth was monitored as described in Materials and Methods. Values
representmean±SEM. (B) Scatter plots of photons per second from PC-3lucMock and PC-3lucCCL2 on the fifth week. Values representmedian
(*P < .05). (C) Representative pictures illustrate week 5 images from each group (left panel, PC-3lucMock; right panel, PC-3lucCCL2).
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in bone activity undergoing bone resorption [28], suggesting that
OCs found in PC-3lucCCL2 bone metastases (Figure 6D, arrowheads)
were activated.
Discussion
Prostate cancer is an incurable disease once it metastasizes to other
organs. It is well established that the tumor microenvironment plays
a critical role in the “vicious cycle” of tumorigenesis by the enrich-
ment of growth factors from component cells [4–7,9–13]. CCL2 is
produced by macrophages, fibroblasts, endothelial cells, and cancer
cells. CCL2 is one of the tumor microenvironment–derived signals
that recruit TAMs, originating from circulating monocytes in tumor-
related vasculature [5,29]. It has been previously demonstrated that
CCL2-neutralizing antibodies effectively inhibited prostate cancer
Figure 4. Effects of target treatment of CCL2 on local PC-3luc tumor growth and macrophage recruitment. (A) Mice received PBS (control)
or a combination of anti–human CCL2 CNTO888 (10 mg/kg) and anti–mouse CCL2/JE CNTO1142 (10 mg/kg) from 1 week before PC-3luc
subcutaneous injection (n = 5 per group) to the end of the experiment twice weekly. Tumor growth was recorded as photons per second,
and data from the fifth week were plotted. Values represent median (*P < .05). (B) Macrophage recruitment to tumor. Tumors were
harvested on the sixth week, and the percentage of Mac-3-positive cells were analyzed as described in Materials and Methods. Values
represent mean ± SEM (*P < .05, Student’s t test).
Figure 3. Macrophage recruitment to prostate cancer xenografts. (A) Representative results show macrophage infiltration into tumors.
Local tumor xenografts for flow cytometric analysis were generated as described in Materials and Methods. At week 4, tumors were
harvested, and mouse macrophages stained with fluorescein isothiocyanate–conjugated anti–mouse Mac-3 antibody were analyzed by
flow cytometry. (B) Graphical representation of the percentage recruited macrophages percentage in tumor. Values represent mean ±
SEM (*P < .05). (C) Representative pictures of immunostaining analysis of Mac-3-positive cells in each group tumors. Bars, 50 μm.
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Figure 5. In vivo analysis of PC-3lucMock and PC-3lucCCL2 metastases. (A) Mice received PC-3lucMock and PC-3lucCCL2 cells by intracardiac
injection (PC-3lucMock, n = 14; PC-3lucCCL2, n = 15), and overall tumor burden was monitored as photons per second. Values repre-
sent mean ± SEM. (B) Scatter plots of photons per second from whole body at week 7. Values represent median (*P < .05). (C) On
the seventh week, jaw and bilateral lower limb–specific tumor burden was recorded as bone metastases and plotted (PC-3lucMock =
15 metastases/14 mice, PC-3lucCCL2 = 24 metastases/15 mice). Values represent median (*P < .05). Representative pictures illustrate
week 7 images from each group (left panel, PC-3lucMock; right panel, PC-3lucCCL2).
Figure 6. Osteoclasts in bone metastases. (A) Tartrate-resistant acid phosphatase staining of PC-3lucMock and PC-3lucCCL2 bone metastasis.
(B) High-magnification picture of TRAP-positive multinuclear cells in PC-3lucCCL2. Howship lacunae (bone resorption lacunae) by OC were
observed (arrowheads). (C) The number of TRAP-positive multinuclear cells on bone surface per 1 mm was manually counted by micros-
copy. Values represent mean ± SEM (*P < .05). Bars, 100 μm.
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growth in vivo [16]. Here, the in vivo data further demonstrate the
importance of CCL2 in prostate cancer bone metastasis by mediating
TAM and OC recruitment and function.
To confirm the role of CCL2 in the tumor microenvironment, a
human CCL2 high-expression cell line, PC-3lucCCL2 was generated.
Proliferation of PC-3lucMock and PC-3lucCCL2 in vitro was not signifi-
cantly different. These data suggest that the main effect of CCL2 on
cancer cell growth is not through direct stimulation of growth but
rather through indirect effects on host cells of the microenvironment.
Migration assay data confirmed the cross-reactivity of human CCL2
fromPC-3lucCCL2 cells on SCIDmousemacrophages. In accordancewith
these findings, other researchers have shown that humanCCL2 has cross-
reactivity on mouse macrophages [20]. Thus, it is reasonable to believe
that human CCL2 in these experiments can act on mouse macrophages
in vivo. The numbers of migrated cells were similar in PC-3lucMock con-
ditioned medium and rhCCL2-induced migrated cells and were higher
than those in the control. Numerous factors that recruit PBMCs to the
tumor microenvironment were reported [11]. Our data regarding several
chemotactic factors (e.g., transforming growth factor β and macrophage
inflammatory protein-1) from PC-3 cells (data not shown) may explain
this result.
These studies demonstrated that overexpression of CCL2 in human
prostate cancer cells significantly increased local tumor burden in vivo.
Tumor cell growth rate in vivo showed a significant increase compared
with the in vitro data. One possible explanation for this phenomenon
includes the attraction of tumor promoting TAMs [9–12]. In the present
study, the number of macrophages identified with anti–mouse Mac-3
antibody in PC-3lucCCL2 is higher compared with that in PC-3lucMock.
Targeted treatment of human and mouse CCL2 reduced recruitment
of macrophages to the tumor with a subsequent decrease in tumor
growth. Further experiments to determine the precise characterization
of macrophages and the factors that contribute to tumor progression
from TAMs are ongoing.
Bone is the most preferred metastasis site of advanced prostate
cancer. More than 80% of patients who died with prostate cancer
had evidence of gross bone metastasis. [4,5]. Although prostate cancer
is a prototypic osteoblastic tumor, bone resorption by OCs is known
to be the key step of bone metastasis [24–27]. A large number of re-
searchers have published their findings on tumor-induced OC for-
mation in recent years [30–32]. CCL2 has been reported to be a key
mediator of prostate cancer–induced osteoclastogenesis in vivo and
in vitro [28,33]. We have reported that CCL2 did not affect human
CD11b+ PBMCs OC formation and bone resorption in vitro [34].
This discrepancy may come from the population difference in human
bone marrow mononuclear cells and purified PBMCs. To explore this
discrepancy, tumor burden by intracardiac injection was studied to in-
vestigate the role of CCL2 in metastasis, especially in bone. The present
data indicate that overexpression of CCL2 promotes prostate cancer
bone metastasis. Although there was no statistically significant difference
in bone metastasis numbers, PC-3lucCCL2 grew at a significantly higher
rate in bone. This is expected because CCL2 is known to be important in
attracting monocytes to the tumor microenvironment. Hematopoietic
stem cells give rise to several types of blood cells including macrophages
andOCs [35]. CCL2was identified as the promotingmigration factor of
monocytes and macrophages to sites of inflammation and as an activator
of OCs. Osteoclasts play a critical role in the “vicious cycle” of the tumor
bone microenvironment [4,5]. Bone is a growth factor–rich soil, and
the destruction of bone by OCs releases many growth factors, resulting
in tumor growth [21,23,24,30,36]. Previous studies with a neutralizing
antibody and short hairpin RNA for CCL2 have reported that CCL2 is
a critical mediator for prostate cancer–induced osteoclastogenesis and
bone resorption [30,33]. The combination of previous and current data
suggests that CCL2 recruits OC precursor cells to bone metastasis sites
and promotes OC formation and the consequent release of numerous
factors that promote tumor growth. Precise analysis of dominant
growth factors in a CCL2-rich bone microenvironment is needed.
In summary, these results indicate that CCL2 plays a positive reg-
ulatory role on human prostate cancer growth and bone metastasis
in vivo. CCL2 promotes tumor growth through recruitment of macro-
phages and OCs. Clinical investigation is necessary to determine the
efficacy of an anti-CCL2 antibody in prostate cancer patients who has
metastatic disease, especially those with bone metastasis.
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